Bacterial gene therapy strategies
- 17 December 2005
- journal article
- review article
- Published by Wiley in The Journal of Pathology
- Vol. 208 (2) , 290-298
- https://doi.org/10.1002/path.1865
Abstract
The ability of bacteria to mediate gene transfer has only recently been established and these observations have led to the utilization of various bacterial strains in gene therapy. The types of bacteria used include attenuated strains of Salmonella, Shigella, Listeria, and Yersinia, as well as non‐pathogenic Escherichia coli. For some of these vectors, the mechanism of DNA transfer from the bacteria to the mammalian cell is not yet fully understood but their potential to deliver therapeutic molecules has been demonstrated in vitro and in vivo in experimental models. Therapeutic benefits have been observed in vaccination against infectious diseases, immunotherapy against cancer, and topical delivery of immunomodulatory cytokines in inflammatory bowel disease. In the case of attenuated Salmonella, used as a tumour‐targeting vector, clinical trials in humans have demonstrated the proof of principle but they have also highlighted the need for the generation of strains with reduced toxicities and improved colonization properties. Altogether, the encouraging results obtained in the studies presented in this review justify further development of bacteria as a therapeutic vector against many types of pathology. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 94 references indexed in Scilit:
- Systemic Administration of an Attenuated, Tumor-TargetingSalmonella typhimuriumto Dogs with Spontaneous Neoplasia: Phase I EvaluationClinical Cancer Research, 2005
- Immunogenicity against Human Papillomavirus Type 16 Virus-Like Particles Is Strongly Enhanced by the PhoPcPhenotype inSalmonella entericaSerovar TyphimuriumInfection and Immunity, 2004
- Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patientsCancer Gene Therapy, 2003
- Recombinant E. coli efficiently delivers antigen and maturation signals to human dendritic cells: Presentation of MART1 to CD8+ T cellsInternational Journal of Cancer, 2003
- A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapyGene Therapy, 2002
- Radio-responsive recA promoter significantly increases TNFα production in recombinant clostridia after 2 Gy irradiationGene Therapy, 2001
- Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicumCancer Gene Therapy, 2001
- Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain ofSalmonella typhimuriumThe Journal of Infectious Diseases, 2000
- Bacterial pathogenesis: Common entry mechanismsCurrent Biology, 1996
- Clostridial oncolysis in manEuropean Journal of Cancer (1965), 1967